Veterans with apnea-hypopnea index scores implying no sleep apnea or severe sleep apnea had higher all-cause mortality rates ...

Tirzepatide, a GLP-1 medication already on the market to treat diabetes, is now FDA approved to help those suffering from ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for motor vehicle accidents (MVA) compared with continuous positive airway pressure (CPAP ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...

For years, Michelle Strickland had trouble sleeping – she woke up several times at night – and it left her with daytime sleepiness and her body craving lots of naps. Strickland recently went ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...